Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01222416 · ClinicalTrials.gov registry record · NA
PET/CT Evaluation of Treatment Response in Breast Cancer
A NA study, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT01222416 is a NA study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 50 participants.
The verdict
NCT01222416, a NA study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to develop Positron Emission Tomography (PET) - Computed Tomography (CT) PET/CT imaging methods for looking at the effects of chemotherapy in breast cancer.
Interventions
- RADIATION Radiopharmaceutical Administration [18F]-FDG
- RADIATION Radiopharmaceutical: [18F]-FLT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-10 |
| Est. Completion | 2015-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01222416
The ClinicalTrials.gov registry entry for NCT01222416 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Radiopharmaceutical Administration [18F]-FDG is the first listed.
NCT01222416 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01222416 about?
NCT01222416 is a clinical study titled "PET/CT Evaluation of Treatment Response in Breast Cancer". The purpose of this study is to develop Positron Emission Tomography (PET) - Computed Tomography (CT) PET/CT imaging methods for looking at the effects of chemotherapy in breast cancer.
What is the current status of trial NCT01222416?
This trial is currently terminated. It is a NA study. The enrollment target is 50 participants. The study started on 2010-10. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01222416?
The interventions under investigation include: Radiopharmaceutical Administration [18F]-FDG (RADIATION), Radiopharmaceutical: [18F]-FLT (RADIATION).
Who is sponsoring clinical trial NCT01222416?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.